Reports

LETTERS TO THE EDITOR

Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statement

 Source: IMF Myeloma Minute 22 May 2007

- Findings Show Survival Improvement with Lower Doses of Dexamethasone, the Steroid Commonly Used with REVLIMID® and other Drugs in Newly Diagnosed Myeloma -
- Findings Challenge Traditional Assumption that More-Is-Better when Treating Cancer -

The following report on the International Myeloma Workshop in Kos, was written by Greetje Goossens, a myeloma patient herself and one of the European Myeloma Platform counsellors. She attended the workshop together with 3 other members of EMP. She looks at the information obtained at this workshop from a patients’ perspective.

This workshop is a part of the Capoira project (The Capacity Building for Patient Organisations in Research Activities).